HFS
HBIO icon

Hantz Financial Services’s Harvard Bioscience HBIO Stock Holding History

Hantz Financial Services’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Hold
0
– – – 1150
2024
Q1 		– Hold
0
– – – 1234
2021
Q3 		– Sell
-80
Closed -$7K – 831
2021
Q2 		$7K Buy
+80
New +$5.66K ﹤0.01% 707

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Hantz Financial Services's HBIO Position: Q2 2024 in Review

Hantz Financial Services held its Harvard Bioscience (HBIO) position steady in Q2 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

Hantz Financial Services first reported a position in HBIO in Q2 2021 and has held it in 1 quarter since. The position peaked at $7K in Q2 2021. 100 funds tracked by Wall St. Rank hold HBIO as of Q2 2024.

  • Hantz Financial Services held 0 shares of Harvard Bioscience worth $0 as of Q2 2024.
  • Hantz Financial Services left its Harvard Bioscience share count unchanged in Q2 2024.
  • Harvard Bioscience made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2024, its #1150 holding.
  • Hantz Financial Services first reported a position in Harvard Bioscience in Q2 2021 and has held it in 1 quarter since.
  • Hantz Financial Services's Harvard Bioscience position peaked at $7K in Q2 2021.
  • 100 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2024.

Based on Hantz Financial Services's 13F filing for Q2 2024, filed 30 Jul 2024.